Sustained-release tablets of felodipine joint rosuvastatin of rosuvastatin calcium on blood pressure variability in hypertensive patients
LU Jun-hong
Abstract：Objective To explore the application of felodipine sustained-release tablets joint rosuvastatin of rosuvastatin calcium variability in patients with hypertension.Methods From November 2010 to May 2011,110 patients with hypertension were randomly divided into two groups with 55 cases in each group.Control group patients were given levaml odipine besylate tablets combined with rosuvastatin calcium; the experimental group were given with felodipine horizon sustained-release tablets and rosuvastatin small calcium combination therapy.Before and after 24 weeks of treatment lipids,the average blood pressure and blood pressure variability were compared between two groups.Results The experimental group 24 h after treatment the average systolic blood pressure,diastolic blood pressure in the experimental group were (119 ± 7),(71 ± 4) mm Hg respectively,mean daytime systolic blood pressure,diastolic blood pressure were (118 ± 6),(73 ± 3) mm Hg respectively,mean nighttime systolic blood pressure,diastolic blood pressure were(108 ±8),(73 ±5) mm Hg,respectively,before treatment (165 ± 12),(93 ± 5),(174 ± 16),(99 ± 4),(151 ± 12),(89 ± 6) mm Hg,these indicators after treatment of control group were (135 ± 8),(79 ± 5),(138 ± 7),(83 ± 4),(134 ± 7),(76 ± 7)mm Hg,the experimental group after treatment,mean blood pressure before treatment and the control group after treatment difference was statistically significant (all P ＜ 0.05) ; experimental group 24 h after treatment systolic and diastolic blood pressure were labeled standard deviation (10.6 ±2.2),(8.3 ± 1.6) mm Hg,daytime systolic and diastolic blood pressure standard deviation were (10.3 ± 1.5),(7.1 ± 1.6) mm Hg,nighttime systolic blood pressure,diastolic blood pressure standard deviation were (9.3 ± 1.4),(7.2 ± 1.5) mm Hg,respectively,before treatment (16.5 ± 3.0),(10.9 ± 2.5),(15.2 ± 3.3),(10.4 ± 2.2),(13.3 ± 2.8),(9.6 ± 3.2) mm Hg,control group after treatment of these indicators were (13.9 ±2.3),(9.6 ±1.7),(13.8 ±1.5),(9.2 ±1.4),(12.6 ±1.6),(8.6 ± 1.4) mm Hg,the experimental group after treatment,blood pressure variability and before treatment and control group after treatment was statistically significant (P ＜ 0.05).Conclusion The application of felodipine sustained-release tablets joint rosuvastatin calcium in the treatment of hypertension in patients is safe and effective.
Keywords：Blood pressure variabilityRosuvastatin calciumFelodipine sustained-release tabletsHypertension
Publication Date：2013-09-30
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 1219-1221 )